6.115
前日終値:
$6.23
開ける:
$6.26
24時間の取引高:
122.50K
Relative Volume:
0.16
時価総額:
$488.44M
収益:
$73.48M
当期純損益:
$-108.30M
株価収益率:
-2.7178
EPS:
-2.25
ネットキャッシュフロー:
$-67.17M
1週間 パフォーマンス:
+4.69%
1か月 パフォーマンス:
+23.94%
6か月 パフォーマンス:
+72.33%
1年 パフォーマンス:
+386.90%
Personalis Inc Stock (PSNL) Company Profile
PSNL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PSNL
Personalis Inc
|
6.115 | 488.44M | 73.48M | -108.30M | -67.17M | -2.25 |
![]()
TMO
Thermo Fisher Scientific Inc
|
391.88 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
195.49 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
518.46 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
115.93 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
154.23 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-15 | 開始されました | Guggenheim | Buy |
2025-03-17 | 開始されました | Craig Hallum | Buy |
2023-02-06 | アップグレード | Needham | Hold → Buy |
2022-01-07 | アップグレード | BofA Securities | Neutral → Buy |
2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-11-03 | ダウングレード | Needham | Buy → Hold |
2021-10-15 | 再開されました | Cowen | Outperform |
2021-09-20 | 繰り返されました | Needham | Buy |
2021-05-06 | アップグレード | Oppenheimer | Perform → Outperform |
2021-01-28 | 開始されました | Truist | Buy |
2021-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
2020-11-12 | 繰り返されました | Needham | Buy |
2020-11-06 | ダウングレード | Oppenheimer | Outperform → Perform |
2020-10-19 | 開始されました | Citigroup | Buy |
2020-10-08 | 開始されました | BTIG Research | Buy |
2020-08-27 | 開始されました | H.C. Wainwright | Buy |
2020-08-18 | 開始されました | Needham | Buy |
2019-09-26 | アップグレード | BofA/Merrill | Neutral → Buy |
2019-07-15 | 開始されました | BofA/Merrill | Neutral |
2019-07-15 | 開始されました | Cowen | Outperform |
2019-07-15 | 開始されました | Morgan Stanley | Overweight |
2019-07-15 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Personalis Inc (PSNL) 最新ニュース
The 13% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 394% - Yahoo Finance
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks (NASDAQ:PSNL) - Seeking Alpha
Two Sigma Advisers LP Grows Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Shares Purchased by Two Sigma Investments LP - Defense World
Ameriprise Financial Inc. Has $199,000 Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Bank of America Corp DE Sells 30,474 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy - MSN
Personalis reveals ctDNA test predicts cervical cancer relapse By Investing.com - Investing.com South Africa
Personalis reveals ctDNA test predicts cervical cancer relapse - Investing.com Australia
Personalis (PSNL) Blood Test Shows Promise in Detecting Cervical Cancer Early | PSNL Stock News - GuruFocus
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - Yahoo Finance
Personalis Says Studies Show NeXT Personal Test Could Identify Relapse Risk in Breast Cancer Patients - marketscreener.com
Personalis (PSNL) Showcases Promising Results for NeXT Personal in Breast Cancer Care | PSNL Stock News - GuruFocus
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Yahoo Finance
Northern Trust Corp Lowers Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Millennium Management LLC Has $7.61 Million Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
BNP Paribas Financial Markets Acquires 71,721 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis and Academic Partners to Present Latest Data on Ultra - GuruFocus
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection - Yahoo Finance
New Clinical Data Reveals Groundbreaking Early Cancer Detection ResultsPersonalis ASCO Preview - Stock Titan
Personalis Holds Virtual Annual Stockholders Meeting - TipRanks
PSNL to Discuss Future Plans in Upcoming Virtual Meeting | PSNL Stock News - GuruFocus
Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $8.00 - Defense World
Personalis Inc (PSNL): A Sitting Duck With -162.63% Upside Potential - Stocksregister
Guggenheim Begins Coverage on Personalis (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stake Raised by Jane Street Group LLC - Defense World
Jane Street Group LLC Has $2.32 Million Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
Personalis, Inc. (NASDAQ:PSNL) Shares Acquired by Stifel Financial Corp - Defense World
Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Ta - GuruFocus
Guggenheim starts Personalis with a Buy, cites ‘best-in-class infrastructure’ - TipRanks
Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Target | PSNL Stock News - GuruFocus
Guggenheim Initiates Personalis at Buy With $6 Price Target - marketscreener.com
Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating - GuruFocus
Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating | PSNL Stock News - GuruFocus
Dimensional Fund Advisors LP Purchases 242,141 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Raymond James Financial Inc. Takes Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Leading Genomics Company Personalis Takes Center Stage at Major Craig-Hallum Investor Conference - Stock Titan
Personalis stock price target raised to $9 at H.C. Wainwright By Investing.com - Investing.com Nigeria
What is HC Wainwright’s Estimate for Personalis Q2 Earnings? - Defense World
Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth - MSN
HC Wainwright Raises Personalis (NASDAQ:PSNL) Price Target to $9.00 - Defense World
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - MSN
Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth - Yahoo Finance
Barclays PLC Acquires 43,900 Shares of Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
JPMorgan Chase & Co. Has $34,000 Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Barclays PLC Increases Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis stock price target raised to $9 at H.C. Wainwright - Investing.com Australia
Personalis Inc.: Strong Financial Performance and Promising Future Prospects Drive Buy Rating - TipRanks
Will Personalis' Testing Growth And MRD Strategy Pay Off In 2025? - Nasdaq
Personalis Inc (PSNL) 財務データ
収益
当期純利益
現金流量
EPS
Personalis Inc (PSNL) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Moore Stephen Michael | SVP and Chief Legal Officer |
May 16 '25 |
Sale |
4.95 |
1,675 |
8,291 |
64,200 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
May 16 '25 |
Sale |
4.95 |
910 |
4,504 |
124,957 |
Tachibana Aaron | CFO AND COO |
Jan 28 '25 |
Sale |
5.79 |
708 |
4,099 |
166,390 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jan 28 '25 |
Sale |
5.79 |
519 |
3,005 |
123,367 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Dec 16 '24 |
Sale |
3.82 |
4,834 |
18,466 |
123,886 |
Moore Stephen Michael | SVP and Chief Legal Officer |
Dec 16 '24 |
Sale |
3.82 |
1,513 |
5,780 |
65,875 |
Tachibana Aaron | CFO AND COO |
Dec 16 '24 |
Sale |
3.82 |
6,865 |
26,224 |
167,098 |
Tachibana Aaron | CFO AND COO |
Nov 18 '24 |
Sale |
3.79 |
1,307 |
4,954 |
173,963 |
Moore Stephen Michael | SVP and Chief Legal Officer |
Nov 18 '24 |
Sale |
3.79 |
1,693 |
6,416 |
67,388 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Nov 18 '24 |
Sale |
3.79 |
921 |
3,491 |
128,720 |
大文字化:
|
ボリューム (24 時間):